Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), Formula (II), or Formula (III), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: An aspect of the present description relates to compounds useful for improving pre-mRNA splicing in a cell. In particular, another aspect of the present description relates to substituted heteroaryl compounds, forms, and pharmaceutical compositions thereof and methods of use for treating or ameliorating spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD).

Abstract: The present description relates to compounds of formula (I) useful for improving pre-mRNA splicing in a cell. In particular, another aspect described herein relates to substituted pyrrolo[2,3-d]pyrimidine compounds, forms, and pharmaceutical compositions thereof and methods of use for treating or ameliorating familial dysautonomia.

Abstract: The present description relates' to compounds of formula (I) useful for improving pre-mRNA splicing in a cell. In particular, another aspect of the present description relates to substituted thieno[3,2-b]pyridine compounds, forms, and pharmaceutical compositions thereof and methods of use for treating or ameliorating familial dysautonomia.

Abstract: Disclosed are quinoline and quinazoline compounds which modulate the activity of the gated ion channels. Compounds that modulate these gated ion channels are useful in the treatment of diseases and disorders related to pain, inflammation, the neurological system, the gastrointestinal system and genitourinary system. Preferred compounds include quinoline or quinazoline derivatives substituted at the 4-position via N(H), C(O) or O moieties.

Abstract: The present description relates to methods of treating spinocerebellar ataxia type 3 (SCA3) using substituted thieno[3,2-b]pyridine compounds, forms, and pharmaceutical compositions thereof.

Abstract: The present description relates to methods of treating spinocerebellar ataxia type 3 (SCA3) using substituted thieno[3,2-d]pyrimidine compounds, forms, and pharmaceutical compositions thereof.

Abstract: The present description relates to methods of treating spinocerebellar ataxia type 3 (SCA3) using substituted pyrrolo[2,3-d]pyrimidine compounds, forms, and pharmaceutical compositions thereof.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: The present description relates to compounds useful for improving pre-mRNA splicing in a cell. In particular, another aspect of the present description relates to substituted thieno [3,2-d]pyrimidine compounds, forms, and pharmaceutical compositions thereof and methods of use for treating or ameliorating familial dysautonomia.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), Formula (II), or Formula (III), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: The present description relates to compounds of formula (I) useful for improving pre-mRNA splicing in a cell. In particular, another aspect described herein relates to substituted pyrrolo[2,3-d]pyrimidine compounds, forms, and pharmaceutical compositions thereof and methods of use for treating or ameliorating familial dysautonomia.

Abstract: The present description relates' to compounds of formula (I) useful for improving pre-mRNA splicing in a cell. In particular, another aspect of the present description relates to substituted thieno[3,2-b]pyridine compounds, forms, and pharmaceutical compositions thereof and methods of use for treating or ameliorating familial dysautonomia.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: A new and distinct cultivar of Oenothera drummondii identified as TX-12-5 characterized by 1) a propensity for free flowering (numerous flowers over an extended time and range of photoperiods), 2) a low spreading growth habit (typically less than 30 cm tall) with a dense canopy of foliage, 3) a grey-green shade of foliage compared to the green of most of the species, and 4) consistently bright yellow flowers.

Abstract: An electrical brain contact device and device for connecting a plurality of lead wires with individual take-up terminals is described. The lead wires in the brain contact device extend to a terminal mount with an array of lead-wire terminals on it. A connector assembly includes a connector block with a matching array of take-up terminals and an elongate cavity to receive the terminal mount, and a mechanism to removably draw the take-up terminals into terminal-to-terminal contact with the terminal mount to facilitate electrical connection.

Abstract: This invention relates to a CSF shunting system that can be used in the human body for the control of hydrocephalus or excess cerebrospinal fluid (CSF) in the ventricles of the brain. The invention relates to the configuration of a fluid pressure controlling diaphragm which has a substantially planar, non-arched, or slightly convex occluding surface that contacts as its valve mechanism a non-planar opposing surface. The diaphragm element can be made out of silicone rubber or some other flexible material, and the opposing surface can be made from a dissimilar material from the diaphragm element to prevent sticking. The invention also relates to the configuration of this substantially flat diaphragm element, its central stem, and its mounting in a frame so as to facilitate pre-loads, calibrations, and optical, as well as mechanical, tests for quality assurance.

Abstract: A new and distinct cultivar of Oenothera drummondii identified as TX-12-5 characterized by 1) a propensity for free flowering (numerous flowers over an extended time and range of photoperiods), 2) a low spreading growth habit (typically less than 30 cm tall) with a dense canopy of foliage, 3) a grey-green shade of foliage compared to the green of most of the species, and 4) consistently bright yellow flowers.